The HelioLiver test delivers superior performance characteristics when compared to traditional blood tests for hepatocellular carcinoma.
|Early Stage Sensitivity||76%||57%||65%|
Richard Van Etten, MD, PhD
Chief Medical Advisor
Chief Bioinformatics Advisor
Mindie Nguyen, MD, MAS, AGAF, FAASLD
Hepatology Advisor and Lead Principal Investigator in CLiMB
Robert Gish, MD
The Hepatitis B Foundation
We are dedicated to continued evidence generation on the HelioLiver test. Helio Genomics is currently engaged in multiple pivotal, multi-center trials in the US and China.
A multi-center, prospective study conducted in the US to compare the sensitivity and specificity of the HelioLiver Test with ultrasound within a population at high risk of HCC due to liver cirrhosis.
A prospective RO1 study sponsored by NCI in collaboration with Mount Sinai and other medical institutions on the US to evaluate novel screening modalities and biomarkers.
A study to define the performance characteristics of the HelioLiver Test within a study population of subjects that have been diagnosed with liver cancer at various stages (I to IV).
A large-scale multi-center study to evaluate the performance characteristics of the HelioLiver test within a population of subjects diagnosed with HCC and surveillance subjects with liver disease.
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Rui-Hua Xu, Wei Wei, Michal Krawczyk, Wenqiu Wang, Huiyan Luo, Ken Flagg, Shaohua Yi...
Cellular Heterogeneity-Adjusted cLonal Methylation (CHALM) improves prediction of gene expression
Jianfeng Xu, Jiejun Shi, Xiaodong Cui, Ya Cui, Jingyi Jessica Li, Ajay Goel, Xi Chen, Jean-Pierre Issa, Jianzhong Su, Wei Li
DNA methylation markers for diagnosis and prognosis of common cancers
Xiaoke Hao, Huiyan Luo, Michal Krawczyk, Wei Wei, Wenqiu Wang, Juan Wang, Ken Flagg, Jiayi Hou, Heng Zhang, Shaohua Yi...